Alto Neuroscience, Inc. (NYSE:ANRO) Receives $23.83 Consensus Target Price from Brokerages

by · The Cerbat Gem

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $23.8333.

ANRO has been the subject of a number of research reports. Wall Street Zen upgraded Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Robert W. Baird lifted their price target on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Jefferies Financial Group boosted their price objective on shares of Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Chardan Capital raised shares of Alto Neuroscience to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, October 8th.

Read Our Latest Analysis on Alto Neuroscience

Alto Neuroscience Trading Up 1.2%

ANRO stock opened at $13.68 on Wednesday. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. The company has a market cap of $424.88 million, a price-to-earnings ratio of -5.97 and a beta of 2.90. The business has a fifty day simple moving average of $9.73 and a 200-day simple moving average of $5.32. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $16.49.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. On average, equities research analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Large investors have recently modified their holdings of the stock. Armistice Capital LLC raised its holdings in shares of Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after buying an additional 12,000 shares during the period. Susquehanna International Group LLP grew its position in Alto Neuroscience by 154.9% in the third quarter. Susquehanna International Group LLP now owns 155,676 shares of the company’s stock valued at $626,000 after acquiring an additional 94,613 shares in the last quarter. Millennium Management LLC raised its stake in shares of Alto Neuroscience by 4.3% during the third quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock valued at $1,269,000 after purchasing an additional 12,896 shares during the period. Two Sigma Investments LP lifted its position in shares of Alto Neuroscience by 160.6% during the third quarter. Two Sigma Investments LP now owns 116,579 shares of the company’s stock worth $469,000 after purchasing an additional 71,844 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of Alto Neuroscience by 43.5% during the third quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company’s stock worth $312,000 after purchasing an additional 23,553 shares in the last quarter.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Recommended Stories